Brokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Price Target at $78.40

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, seven have assigned a buy recommendation and one has issued […]

Related Keywords

United States ,Wisconsin ,America ,Robertw Baird ,Candace Rose Depp ,A Sinclair Dunlop ,Pascal Deschatelets ,Cedric Francois ,Raymond James ,Stifel Nicolaus ,Pier Capital ,Apellis Pharmaceuticals Company Profile ,Stelac Advisory Services ,Apellis Pharmaceuticals ,News Ratings For Apellis Pharmaceuticals Daily ,Wells Fargo Company ,Apellis Pharmaceuticals Trading ,Macquarie Group Ltd ,Insider Transactions At Apellis Pharmaceuticals ,Apellis Pharmaceuticals Inc ,Analyst Recommendations For Apellis Pharmaceuticals ,Nasdaq ,Get Rating ,Wisconsin Investment Board ,Alec Machiels ,Apellis Pharmaceuticals Daily ,Nasdaq Apls ,Apls ,Medical ,Ratings ,Consensus ,